Clinical and Research Microbiome Center, Research Division, Rambam Health Care Campus, Haifa, Israel.
Clinical Microbiology Laboratories, Laboratories Division, Rambam Health Care Campus, Haifa, Israel.
Front Cell Infect Microbiol. 2022 Oct 19;12:955481. doi: 10.3389/fcimb.2022.955481. eCollection 2022.
We hypothesized that targeted NGS sequencing might have an advantage over Sanger sequencing, especially in polymicrobial infections. The study included 55 specimens from 51 patients. We compared targeted NGS to Sanger sequencing in clinical samples submitted for Sanger sequencing. The overall concordance rate was 58% (32/55) for NGS vs. Sanger. NGS identified 9 polymicrobial and 2 monomicrobial infections among 19 Sanger-negative samples and 8 polymicrobial infections in 11 samples where a 16S gene was identified by gel electrophoresis, but could not be mapped to an identified pathogen by Sanger. We estimated that NGS could have contributed to patient management in 6/18 evaluated patients and thus has an advantage over Sanger sequencing in certain polymicrobial infections.
我们假设靶向 NGS 测序可能比 Sanger 测序具有优势，尤其是在多微生物感染中。该研究包括 51 名患者的 55 个样本。我们将靶向 NGS 与临床样本提交的 Sanger 测序进行比较。NGS 与 Sanger 的总符合率为 58%（32/55）。NGS 在 19 个 Sanger 阴性样本中发现了 9 种混合微生物感染和 2 种单微生物感染，在 11 个通过凝胶电泳鉴定出 16S 基因但无法通过 Sanger 映射到鉴定病原体的样本中发现了 8 种混合微生物感染。我们估计，NGS 可能有助于评估的 18 名患者中的 6 名患者的治疗，因此在某些多微生物感染中优于 Sanger 测序。
